Menopause is not a single event - it is a transition that unfolds over years. And while hot flashes and missed periods get most of the attention, the hormonal shifts of menopause can affect your brain, bones, heart, metabolism, sleep, and mood.
Lab tests can't pinpoint where you are in this transition. Hormone levels swing so much that FSH and estradiol are of little diagnostic value (Burger, 2011), and menopause itself is defined after 12 months without a period (Mangione et al., 2022). Some tests can still help you and your clinician look at health risks that rise in midlife, and that can help when you're deciding about treatment, including whether hormone replacement therapy (HRT) may be right for you.
Understanding the Menopausal Transition
Perimenopause
The transition can begin in your 40s. In one large US study, its median length ranged from about 4.4 years in women who started latest to about 8.6 years in women who started earliest (Paramsothy et al., 2017). During perimenopause:
- Estrogen can fluctuate widely (Burger, 2011) - a small study found more estrogen by-products in the urine of perimenopausal women than younger women (Santoro et al., 1996), and a larger study found average estradiol began to fall about 2 years before the final period (Randolph et al., 2011)
- Progesterone can fall as cycles without ovulation become more frequent, in the last 30 months or so before the final period (Burger et al., 2008)
- FSH can begin to rise - on average about 6 years before the final period (Randolph et al., 2011)
- Symptoms can emerge: irregular periods, sleep disruption, mood changes, hot flashes. About 50% to 75% of women have hot flashes, night sweats or both (Crandall et al., 2023)
Menopause
Menopause is confirmed after 12 months without a period (Mangione et al., 2022), and it can happen between about 45 and 56 (Crandall et al., 2023). After this point:
- Estradiol can keep falling, then level off about 2 years after the final period (Randolph et al., 2011)
- FSH can rise and stay high, leveling off about 2 years after the final period (Randolph et al., 2011)
- Testosterone can decline with age, but a study of 1,423 women found no separate effect of natural menopause (Davison et al., 2005)
- Heart disease risk can rise (El Khoudary et al., 2020), and bone loss can speed up (Greendale et al., 2012)
Menopause Lab Tests: What They Can and Can't Tell You
1. FSH (Follicle-Stimulating Hormone)
FSH is often ordered to look at menopausal status, and levels can rise as the ovaries slow down. But FSH can swing widely in women with irregular cycles, because cycles with and without ovulation are mixed together. Researchers have found no hormone marker of the early or late transition, which makes FSH or estradiol unreliable for staging one woman (Burger et al., 2008).
Important caveat: A single normal FSH can't rule out perimenopause. Your lab report lists its own reference range, and labs differ.
FSH has a clearer role if periods stop before age 40. There, one high FSH result may support a diagnosis of premature ovarian insufficiency (Panay et al., 2024).
2. Estradiol (E2)
Estradiol is the main form of estrogen. Like FSH, it's unreliable for working out where you are in the transition (Burger et al., 2008). Decisions about hormone therapy weigh your symptoms, age, time since menopause and health risks (North American Menopause Society, 2022).
3. Progesterone
Progesterone can fall as cycles without ovulation become more frequent (Burger et al., 2008). A small study found lower luteal progesterone by-products in perimenopausal women than in younger women (Santoro et al., 1996). Because cycles vary so much, one result can only speak to that cycle.
Don't put heavy or irregular bleeding down to hormones alone. See a clinician for very heavy periods, bleeding between periods, or any bleeding after menopause.
4. Testosterone
A testosterone test can't explain low desire on its own. In a study of 1,021 women, no single androgen level predicted low sexual function (Davis et al., 2005). In trials, testosterone improved sexual function in postmenopausal women, including those with low desire causing distress. No effects were reported on body composition, muscle or thinking, though few women contributed data on these (Islam et al., 2019).
5. Thyroid Panel
Thyroid problems can become more common with age. A study of 7,644 Japanese women found that rise tracked with age, with no distinct change at menopause (Hayashi et al., 2026). Hypothyroidism can bring fatigue, weight gain, memory problems and period changes (Chaker et al., 2025), which can overlap with menopause symptoms, so a clinician may check your thyroid if you have these. Screening people without symptoms isn't recommended (Chaker et al., 2025).
A clinician may start with:
- TSH - a high TSH with a low free T4 may point to hypothyroidism (Chaker et al., 2025)
- Free T4 - the main hormone the thyroid releases
- TPO antibodies - may be added if a clinician suspects Hashimoto thyroiditis, the leading cause of hypothyroidism where iodine intake is adequate (Chaker et al., 2025)
6. Bone Health
Low estrogen can speed up bone turnover (Eastell et al., 2016). In a US study, women lost about 10.6% of spine bone density and 9.1% at the hip over the 10 years around the final period. Most of that loss came from 1 year before to 2 years after it (Greendale et al., 2012).
What may help:
- A bone density scan (DEXA) - osteoporosis is diagnosed with bone density measurements, not a blood test (Eastell et al., 2016). The US Preventive Services Task Force recommends screening for women 65 and older, and for younger postmenopausal women at increased risk (Nicholson et al., 2025)
- Vitamin D (25-hydroxyvitamin D) - the Endocrine Society suggests against routine testing unless there's an established reason, and it found no clear target level (Demay et al., 2024)
7. Cardiovascular Risk Markers
Heart disease is the leading cause of death in women, and risk can rise notably after menopause, though women can develop coronary heart disease several years later than men. Lipids, body composition and blood vessel health can change for the worse during the transition, which makes midlife an important time to look at your risk (El Khoudary et al., 2020).
- Complete lipid panel - total cholesterol, LDL, HDL, triglycerides
- Fasting glucose and HbA1c - the US Preventive Services Task Force recommends diabetes screening for adults 35 to 70 with overweight or obesity (Davidson et al., 2021)
- hsCRP (high-sensitivity C-reactive protein) - the Task Force found the evidence insufficient to add it to standard heart risk assessment (Curry et al., 2018)
- Apolipoprotein B (ApoB) - a National Lipid Association statement says it adds to a standard lipid panel and has been superior to LDL cholesterol in risk assessment (Soffer et al., 2024)
8. Additional Markers
- Iron studies (ferritin, transferrin saturation) - testing should be considered with heavy periods, which can lower iron stores (Auerbach et al., 2025). Ferritin can run higher after menopause: one study found it was about 3 times higher in postmenopausal than premenopausal women (Merlo et al., 2023)
When to Test and How Often
During Perimenopause
- Hormone tests: not needed to track your progress, since no hormone level marks where you are in the transition (Burger et al., 2008)
- Your own record: your bleeding pattern is what the main staging system for reproductive aging uses (Harlow et al., 2012), so note changes in your periods and symptoms
- Other tests: ask your clinician what fits your symptoms and health risks
Post-Menopause
- Routine prevention: ask about lipid, diabetes and bone screening based on your age and risks (Davidson et al., 2021) (Nicholson et al., 2025)
- Before HRT: guidelines advise screening for heart disease and breast cancer risk before starting (Stuenkel et al., 2015)
Your symptoms, age and period history can tell you more about this transition than a hormone level. Tests can add to that picture when there's a reason for them. See what we test.
When HRT May Help
Hormone therapy remains the most effective treatment for hot flashes and night sweats and for genitourinary symptoms of menopause, and it has been shown to prevent bone loss and fracture. Its risks differ by type, dose, how long it's used, how it's taken and when it's started (North American Menopause Society, 2022).
Who May Benefit
- Women with bothersome hot flashes or night sweats (North American Menopause Society, 2022)
- Women with bothersome vaginal or urinary symptoms, where low-dose vaginal estrogen or other options may be used if over-the-counter products don't help (North American Menopause Society, 2022)
- Women who need to prevent bone loss (North American Menopause Society, 2022)
- Women with premature ovarian insufficiency (Panay et al., 2024)
For women under 60 or within 10 years of menopause with no reason to avoid it, the balance of benefit and risk is favorable for hot flashes and bone loss. It appears less favorable for women who start more than 10 years after menopause or after age 60, because of greater absolute risks of heart disease, stroke, blood clots and dementia (North American Menopause Society, 2022).
What the Evidence Shows
- Heart disease: hormone therapy isn't recommended to prevent cardiovascular disease (Crandall et al., 2023), and the US Preventive Services Task Force recommends against using it to prevent chronic conditions (Mangione et al., 2022)
- Patches and gels: a meta-analysis found a higher risk of blood clots with oral hormone therapy, but not with non-oral forms. The reviewers reported low to moderate quality evidence (Rovinski et al., 2018)
- Progestogen type: in a large French cohort, estrogen with progesterone wasn't linked with higher breast cancer risk, while estrogen alone and estrogen with most synthetic progestogens were (Fournier et al., 2008). This was an observational study
- Testosterone: a meta-analysis found it effective for postmenopausal women with low sexual desire causing distress. Long-term safety needs more study (Islam et al., 2019)
Lab Monitoring During HRT
Hormone therapy calls for periodic review of its benefits and risks (North American Menopause Society, 2022). Ask your clinician whether you need any blood tests. Estradiol levels on hormone therapy can vary with body weight, alcohol and smoking (Sriprasert et al., 2020), so ask what a result would change before you test.
Tracking Your Transition
Menopause is not one-size-fits-all. Some women have few symptoms, and others find it deeply disruptive. In either case, a clinician can help you:
- Understand your symptoms and what else may be behind them
- Look at your health risks (heart, diabetes, bone) with screening that fits your age and history
- Make informed treatment decisions based on your symptoms, risks and preferences
- Review any treatment over time
Your periods and symptoms can be your best guide to where you are in this transition, and a clinician can help you make sense of them.
References
- Harlow, S. D., et al. (2012). Executive summary of the Stages of Reproductive Aging Workshop +10. Journal of Clinical Endocrinology & Metabolism, 97(4), 1159-1168. PMID 22344196
- The North American Menopause Society. (2022). The 2022 hormone therapy position statement of The North American Menopause Society. Menopause, 29(7), 767-794. PMID 35797481
- Randolph, J. F., et al. (2011). Change in follicle-stimulating hormone and estradiol across the menopausal transition. Journal of Clinical Endocrinology & Metabolism, 96(3), 746-754. PMID 21159842
- Eastell, R., et al. (2016). Postmenopausal osteoporosis. Nature Reviews Disease Primers, 2, 16069. PMID 27681935
- El Khoudary, S. R., et al. (2020). Menopause transition and cardiovascular disease risk: implications for timing of early prevention: a scientific statement from the American Heart Association. Circulation, 142(25), e506-e532. PMID 33251828
- Burger, H. G. (2011). Unpredictable endocrinology of the menopause transition: clinical, diagnostic and management implications. Menopause International, 17(4), 153-154. PMID 22120939
- Burger, H. G., et al. (2008). Cycle and hormone changes during perimenopause: the key role of ovarian function. Menopause, 15(4 Pt 1), 603-612. PMID 18574431
- Mangione, C. M., et al. (2022). Hormone Therapy for the Primary Prevention of Chronic Conditions in Postmenopausal Persons: US Preventive Services Task Force Recommendation Statement. JAMA, 328(17), 1740-1746. PMID 36318127
- Crandall, C. J., et al. (2023). Management of Menopausal Symptoms: A Review. JAMA, 329(5), 405-420. PMID 36749328
- Paramsothy, P., et al. (2017). Duration of the menopausal transition is longer in women with young age at onset: the multiethnic Study of Women's Health Across the Nation. Menopause, 24(2), 142-149. PMID 27676632
- Santoro, N., et al. (1996). Characterization of reproductive hormonal dynamics in the perimenopause. Journal of Clinical Endocrinology & Metabolism, 81(4), 1495-1501. PMID 8636357
- Davison, S. L., et al. (2005). Androgen levels in adult females: changes with age, menopause, and oophorectomy. Journal of Clinical Endocrinology & Metabolism, 90(7), 3847-3853. PMID 15827095
- Greendale, G. A., et al. (2012). Bone mineral density loss in relation to the final menstrual period in a multiethnic cohort: results from the Study of Women's Health Across the Nation (SWAN). Journal of Bone and Mineral Research, 27(1), 111-118. PMID 21976317
- Davis, S. R., et al. (2005). Circulating androgen levels and self-reported sexual function in women. JAMA, 294(1), 91-96. PMID 15998895
- Islam, R. M., et al. (2019). Safety and efficacy of testosterone for women: a systematic review and meta-analysis of randomised controlled trial data. Lancet Diabetes & Endocrinology, 7(10), 754-766. PMID 31353194
- Hayashi, S., et al. (2026). Menopausal Transition and Thyroid Function Trajectories: A Large-Scale Longitudinal Study of Healthy Women. Journal of Clinical Endocrinology & Metabolism, dgag337. PMID 42615120
- Chaker, L., et al. (2025). Hypothyroidism: A Review. JAMA, 334(19), 1750-1760. PMID 40900603
- Demay, M. B., et al. (2024). Vitamin D for the Prevention of Disease: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism, 109(8), 1907-1947. PMID 38828931
- Nicholson, W. K., et al. (2025). Screening for Osteoporosis to Prevent Fractures: US Preventive Services Task Force Recommendation Statement. JAMA, 333(6), 498-508. PMID 39808425
- Davidson, K. W., et al. (2021). Screening for Prediabetes and Type 2 Diabetes: US Preventive Services Task Force Recommendation Statement. JAMA, 326(8), 736-743. PMID 34427594
- Curry, S. J., et al. (2018). Risk Assessment for Cardiovascular Disease With Nontraditional Risk Factors: US Preventive Services Task Force Recommendation Statement. JAMA, 320(3), 272-280. PMID 29998297
- Soffer, D. E., et al. (2024). Role of apolipoprotein B in the clinical management of cardiovascular risk in adults: An Expert Clinical Consensus from the National Lipid Association. Journal of Clinical Lipidology, 18(5), e647-e663. PMID 39256087
- Auerbach, M., et al. (2025). Iron Deficiency in Adults: A Review. JAMA, 333(20), 1813-1823. PMID 40159291
- Merlo, F., et al. (2023). Changes in Iron Status Biomarkers with Advancing Age According to Sex and Menopause: A Population-Based Study. Journal of Clinical Medicine, 12(16), 5338. PMID 37629382
- Panay, N., et al. (2024). Evidence-based guideline: premature ovarian insufficiency. Human Reproduction Open, 2024(4), hoae065. PMID 39660328
- Stuenkel, C. A., et al. (2015). Treatment of Symptoms of the Menopause: An Endocrine Society Clinical Practice Guideline. Journal of Clinical Endocrinology & Metabolism, 100(11), 3975-4011. PMID 26444994
- Rovinski, D., et al. (2018). Risk of venous thromboembolism events in postmenopausal women using oral versus non-oral hormone therapy: A systematic review and meta-analysis. Thrombosis Research, 168, 83-95. PMID 29936403
- Fournier, A., et al. (2008). Unequal risks for breast cancer associated with different hormone replacement therapies: results from the E3N cohort study. Breast Cancer Research and Treatment, 107(1), 103-111. PMID 17333341
- Sriprasert, I., et al. (2020). Factors Associated With Serum Estradiol Levels Among Postmenopausal Women Using Hormone Therapy. Obstetrics and Gynecology, 136(4), 675-684. PMID 32925623



